Key result
Sacubitril/valsartan at 200 mg/d and 400 mg/d, but not 100 mg/d, significantly reduced systolic and diastolic blood pressure compared to ARBs.
Why the study?
The blood pressure-lowering effect of ARNi circumvents its administration and titration in patients with borderline hypotension, prompting evaluation of the correlation between dosage and hemodynamic impacts.
Does sacubitril/valsartan at varying doses reduce blood pressure compared to ARBs in individuals with mild-to-moderate systolic hypertension?
Meta-Analysis (n=7,705)
Does sacubitril/valsartan at varying doses reduce blood pressure compared to ARBs in individuals with mild-to-moderate systolic hypertension?
Answers are grounded in this paper and cite their sources.
Sacubitril/valsartan exerts a dose-dependent blood pressure reduction that exceeds ARBs at doses of 200 mg/d and 400 mg/d, providing important hemodynamic context for its use and titration in patients with borderline hypotension.
Context: Angiotensin receptor-neprilysin inhibitor (ARNi) has been established as the standard medication for heart failure. However, the blood pressure (BP)-lowering effect circumvented its administration and titration in patients with borderline hypotension. Aim: This study aimed to determine the correlation between ARNi dosage and hemodynamic impacts. Subjects and Methods: A network meta-analysis was conducted to interrogate the BP impact of ARNi (sacubitril/valsartan 100 mg/d, 200 mg/d, 400 mg/d) and angiotensin receptor blocker (ARB) counterparts. Individuals with mild-to-moderate systolic hypertension were enrolled in respective studies. The outcomes were set as the change from baseline systolic and diastolic BP. Statistical Analysis Used: Network meta-analysis, node-splitting, and inconsistency model methods in Bayesian approach were employed. Results: A total of 14 manuscripts with 7705 subjects were included for pooled analysis. Compared with ARB, sacubitril/valsartan 400 mg/d and 200 mg/d, but not 100 mg/d, were associated with significantly greater reduction effect of systolic and diastolic BP, either by office documentation or 24-h ambulatory monitoring. The BP-lowering effect of sacubitril/valsartan 400 mg/d and 200 mg/d was nevertheless equivalent. Conclusions: ARNi exerts a dose-dependent effect on BP reduction. Such hemodynamic impact exceeds ARB at higher doses.
No takes yet. Share an insight, caveat, or question.
Kao et al. (2023) conducted a meta-analysis in mild-to-moderate systolic hypertension (n=7,705). Angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) vs. Angiotensin receptor blocker (ARB) was evaluated on Change from baseline systolic and diastolic BP. Sacubitril/valsartan at 200 mg/d and 400 mg/d, but not 100 mg/d, significantly reduced systolic and diastolic blood pressure compared to ARBs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: